Microbiome in Multiple Sclerosis: Where Are We, What We Know and Do Not Know

被引：49

作者：

Boziki, Marina Kleopatra ^{[1
]}

Kesidou, Evangelia ^{[1
]}

Theotokis, Paschalis ^{[1
]}

Mentis, Alexios-Fotios A. ^{[2
,3
]}

Karafoulidou, Eleni ^{[1
]}

Melnikov, Mikhail ^{[4
,5
]}

Sviridova, Anastasia ^{[4
,5
]}

Rogovski, Vladimir ^{[6
]}

Boyko, Alexey ^{[4
,5
]}

Grigoriadis, Nikolaos ^{[1
]}

机构：

[1] Aristotle Univ Thessaloniki, AHEPA Gen Hosp, Neurol Univ Dept 2, Thessaloniki 54634, Greece

[2] Hellenic Pasteur Inst, Publ Hlth Labs, Athens 11521, Greece

[3] Univ Thessaly, Lab Microbiol, Univ Hosp Larissa, Sch Med, Larisa 41110, Greece

[4] Pirogov Russian Natl Res Med Univ, Dept Neurol Neurosurg & Med Genet, Moscow 117997, Russia

[5] Fed Ctr Cerebrovasc Pathol & Stroke, Dept Neuroimmunol, Moscow 117342, Russia

[6] Pirogov Russian Natl Res Med Univ, Dept Mol Pharmacol & Radiobiol, Moscow 117997, Russia

来源：

BRAIN SCIENCES | 2020年 / 10卷 / 04期

关键词：

gut microbiome; gut-brain axis; metagenomics; multiple sclerosis; disease-modifying treatments; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GUT-BRAIN AXIS; T-CELLS; INTESTINAL BARRIER; COMMENSAL BACTERIA; ALEMTUZUMAB; TRANSPLANTATION; TRAFFICKING; EFFICACY; MODEL;

D O I：

10.3390/brainsci10040234

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

An increase of multiple sclerosis (MS) incidence has been reported during the last decade, and this may be connected to environmental factors. This review article aims to encapsulate the current advances targeting the study of the gut-brain axis, which mediates the communication between the central nervous system and the gut microbiome. Clinical data arising from many research studies, which have assessed the effects of administered disease-modifying treatments in MS patients to the gut microbiome, are also recapitulated.

引用

页数：17

共 50 条

[1] Remyelination in multiple sclerosis: what do we know and where are we going?
Williams, Anna
[J]. NEURODEGENERATIVE DISEASE MANAGEMENT, 2015, 5 (01) : 49 - 59
[2] Pediatric Multiple Sclerosis: What we know and where are we headed?
MacAllister, William S.
Christodoulou, Christopher
Milazzo, Maria
Preston, Thomas E.
Serafin, Dana
Krupp, Lauren B.
Harder, Lana
[J]. CHILD NEUROPSYCHOLOGY, 2013, 19 (01) : 1 - 22
[3] Supermax prisons - What we know, what we do not know, and where we are going
Pizarro, Jesenia M.
Narag, Raymund E.
[J]. PRISON JOURNAL, 2008, 88 (01): : 23 - 42
[4] What do we know and where do we go?
Vandiver, BJ
[J]. COUNSELING PSYCHOLOGIST, 2002, 30 (01): : 96 - 104
[5] What we know and what we do not know
McDonald, JC
[J]. RADIATION PROTECTION DOSIMETRY, 2005, 113 (02) : 127 - 128
[6] We do not know what we do not know
Spaeth, GL
[J]. OPHTHALMIC SURGERY AND LASERS, 1999, 30 (05): : 337 - 340
[7] Progressive multiple sclerosis and incontinence: what do we know?
Cotterill, N.
Copestake, C.
Weir, I.
Drake, M.
Norton, C.
Wilkins, A.
[J]. MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 126 - 126
[8] Imprinted Genes and Multiple Sclerosis: What Do We Know?
Baulina, Natalia
Kiselev, Ivan
Favorova, Olga
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (03) : 1 - 18
[9] MENSTRUALLY RELATED DISORDERS - WHAT WE DO KNOW, WHAT WE ONLY BELIEVE THAT WE KNOW, AND WHAT WE KNOW THAT WE DO NOT KNOW
HALBREICH, U
[J]. CRITICAL REVIEWS IN NEUROBIOLOGY, 1995, 9 (2-3): : 163 - 175
[10] How Do We "Know" What We "Know?" And Change What We "Know?"
Fosshage, James L.
[J]. PSYCHOANALYTIC DIALOGUES, 2011, 21 (01) : 55 - 74

← 1 2 3 4 5 →